Abstract Library

#1798 Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Patients wth Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study

Introduction: CLARINET demonstrated the antitumour effect of LAN 120mg/28 days (standard interval) in metastatic gastroenteropancreatic NETs. If disease progresses (PD) on this dose, aggressive treatments (eg targeted therapies) are usually offered.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Pavel M, Dromain C, Majdi A, Houchard A,

Keywords: Lanreotide, dosing interval,

#1767 International Patient Survey of Physical, Emotional and Informational Challenges when Living with NETs: Understanding the Unmet Needs

Introduction: The usefulness of information sources used by NET patients is rarely explored by patient surveys of disease burden/impact on daily living, and may be key to optimizing care.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Khan M

Authors: Khan M, Majdi A, Goldstein G, Mellar K, Watts R,

Keywords: net, patients, survey, symptoms, unmet needs,